Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid Antibody Syndrome.

Jacobs1, Levine

  • 1Wayne State University School of Medicine, Department of Neurology, University Health Center, 8C, 4201 St. Antoine, Detroit, MI 48201-2153, USA. bjacobs@med.wayne.edu

Current Treatment Options in Neurology
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

October 18, 2000 8:30-8:45. Problem Solving with FDG Positron Emission Mammography.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2001
Same author

Coarsening of a class of driven striped structures

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2001
Same author

Endogenous interleukin 6 production protects against histopathologic damage in a murine model of ischemia/reperfusion injury.

Current surgery·2000
Same author

Influence of environmental conditions on the activity of the recombinant mannuronan C-5-epimerase AlgE2.

Enzyme and microbial technology·2000
Same author

Anharmonicity of potentials of atoms in potassium hydrogensulfide (KDS) determined by neutron single-crystal diffraction

Acta crystallographica. Section B, Structural science·2000
Same author

Continuous quantum measurement and the emergence of classical chaos

Physical review letters·2000

Diagnosing antiphospholipid antibody syndrome (aPS) after ischemic stroke requires evaluating risk factors and lab results. Treatment strategies vary, with anticoagulation or antiplatelet agents considered, pending further research.

Area of Science:

  • Neurology
  • Rheumatology
  • Hematology

Background:

  • Antiphospholipid antibody syndrome (aPS) is a condition that can cause blood clots, leading to ischemic stroke or transient ischemic attack (TIA).
  • Accurate diagnosis involves assessing clinical presentation, vascular risk factors, and laboratory findings, such as anticardiolipin antibody titers and lupus anticoagulant presence.

Purpose of the Study:

  • To guide the diagnostic and therapeutic approach for patients with ischemic stroke or TIA when antiphospholipid antibody syndrome (aPS) is suspected.
  • To highlight the current lack of definitive randomized controlled trial data for stroke prevention in aPS.

Main Methods:

  • Review of diagnostic criteria and risk factor assessment for aPS in stroke patients.
  • Discussion of therapeutic options including anticoagulation and antiplatelet agents based on clinical and laboratory evidence.

Related Experiment Videos

  • Emphasis on the need for close follow-up and consideration of future randomized controlled trials.

    • Main Results:

    • A higher suspicion for aPS is warranted with fewer vascular risk factors and strong laboratory confirmation (high titers, lupus anticoagulant).
    • Therapeutic strategies range from short-term anticoagulation (INR 2.0-3.0) to antiplatelet agents, depending on individual patient factors.
    • A conservative approach with antiplatelet therapy may be suitable for patients with less definitive aPS evidence.

    Conclusions:

    • The diagnostic confidence of aPS increases with fewer vascular risk factors and more robust laboratory findings.
    • Treatment decisions for stroke prevention in aPS should be individualized, considering the balance of thrombosis risk and treatment risks.
    • Further randomized controlled trials are needed to establish optimal long-term stroke prevention strategies for aPS.